BRAF and colorectal carcinoma: In a phase I/II prospective multicenter study, 34 patients with metastatic CRC were tissue-tested as RAS wild-type and treated with cetuximab; a ctDNA analysis performed as part of this study revealed additional RAS mutations in three patients and BRAF or rare RAS mutations in six others.